Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Trial Profile

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Influenza virus vaccine (NasoVAX) (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Proof of concept
  • Sponsors Altimmune
  • Most Recent Events

    • 27 Mar 2018 Results comparing data from this trial with data from a parallel open label study published in an Altimmune Media Release
    • 15 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Sep 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top